ondansetron has been researched along with Critical Illness in 4 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Critical Illness: A disease or state in which death is possible or imminent.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 4 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tao, L | 1 |
| Zhou, S | 1 |
| Chang, P | 1 |
| An, S | 1 |
| Gray, M | 1 |
| Priyanka, P | 1 |
| Kane-Gill, S | 1 |
| Wang, L | 1 |
| Kellum, JA | 1 |
| Fang, Y | 1 |
| Xiong, C | 1 |
| Wang, X | 1 |
| Boshen, Y | 1 |
| Yuankang, Z | 1 |
| Taixi, L | 1 |
| Kaifan, N | 1 |
| Zhixiang, W | 1 |
| Liang, L | 1 |
| Chengxing, S | 1 |
| Xia, L | 1 |
| Xian, J | 1 |
4 other studies available for ondansetron and Critical Illness
| Article | Year |
|---|---|
Effects of ondansetron use on outcomes of acute kidney injury in critically ill patients: An analysis based on the MIMIC-IV database.
Topics: Acute Kidney Injury; Cohort Studies; Critical Illness; Humans; Intensive Care Units; Ondansetron; Re | 2021 |
Kidney and Mortality Outcomes Associated with Ondansetron in Critically Ill Patients.
Topics: Acute Kidney Injury; Antiemetics; Critical Illness; Humans; Intensive Care Units; Kidney; Metoclopra | 2022 |
Association between early ondansetron administration and in-hospital mortality in critically ill patients: analysis of the MIMIC-IV database.
Topics: Critical Illness; Hospital Mortality; Humans; Intensive Care Units; Ondansetron; Retrospective Studi | 2022 |
Effects of ondansetron treatment on outcomes of critically ill patients with myocardial infarction partly through its anti-inflammatory activity.
Topics: Critical Care; Critical Illness; Humans; Intensive Care Units; Myocardial Infarction; Ondansetron; R | 2023 |